You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

CLINICAL TRIALS PROFILE FOR MPI DTPA KIT - CHELATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Mpi Dtpa Kit - Chelate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00440583 ↗ The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP Completed Bayer Phase 2 2006-09-01 The purpose of this study is to determine the effective of Yt90-Zevalin therapy in patients with diffuse large B-cell lymphoma that have achieved at least an unconfirmed partial remission after 6 cycles of CHOP therapy.
NCT00440583 ↗ The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP Completed Mahidol University Phase 2 2006-09-01 The purpose of this study is to determine the effective of Yt90-Zevalin therapy in patients with diffuse large B-cell lymphoma that have achieved at least an unconfirmed partial remission after 6 cycles of CHOP therapy.
NCT00461149 ↗ Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed Federico II University Phase 4 1995-01-01 Epidemiological data indicate that patients with active acromegaly have reduced life expectancy because of cardiovascular (60%) and respiratory diseases (25%) mainly (1-10). A post-treatment GH value <5 mU/liter (equal to <2.5 μg/liter) and IGF-I in the normal range for age are recognized as the most predictive survival indices. Since their introduction into clinical use approximately two decades ago, somatostatin analogs have been considered a cornerstone of medical therapy for acromegaly. After 12 months of treatment with octreotide-LAR, control of GH and IGF-I excess, is achieved in 54% and 63% of unselected patients (11). The proportion of subjects achieving IGF-I normalization increases significantly with time (12). Significant tumor shrinkage has also been reported in a number of studies (13,14): an average 50% tumor decrease is achieved when the drug is used exclusively, or before surgery or radiotherapy (14). In 99 unselected newly diagnosed patients after 12 months of treatment with somatostatin analogues we reported control of GH levels in 57.6% and IGF-I levels in 45.5% and a greater than 50% tumor shrinkage in 44.4% (15). The dose of LAR in different studies ranged from 10-40 mg every 28 days (q28d): high doses are generally administered in patients who do not control GH and IGF-I excess with lower doses. As reported in the meta-analysis (11) the rate of IGF-I normalization tended to be lower as octreotide-LAR dose was raised: 90% in patients treated with 10 mg, 61% with 20 mg and 53% with 30 mg. However, some further benefit by increasing the dose of octreotide-LAR was reported in some studies (16-18). Data on dose escalation of octreotide-LAR given as first-line therapy in newly diagnosed patients with acromegaly are lacking.
NCT00602316 ↗ Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer Unknown status Royal Marsden NHS Foundation Trust N/A 2007-11-01 RATIONALE: Diagnostic procedures, such as multifunctional magnetic resonance imaging, may help doctors learn the extent of disease and plan the best treatment. PURPOSE: This clinical trial is studying how well multifunctional magnetic resonance imaging works in predicting breast lesions in women undergoing mastectomy for breast cancer.
NCT01059474 ↗ Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion Completed Phoenix Children's Hospital Phase 1 2010-04-01 DMPS is a metal chelator which is approved for use in Europe. While not an FDA-approved drug in the US, it is easily obtained and administered by alternative health practitioners to their patients. A formulation called 'TD DMPS' (transdermal DMPS) is in use, despite the fact there is no published literature to support that the agent is absorbed transdermally. The investigators hypothesis is that DMPS is not absorbed through the skin. The investigators plan to apply TD DMPS to healthy volunteers and then test serum for presence of DMPS. In addition the investigators will measure urinary mercury concentrations pre and post DMPS application.
NCT01059474 ↗ Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion Completed Banner Health Phase 1 2010-04-01 DMPS is a metal chelator which is approved for use in Europe. While not an FDA-approved drug in the US, it is easily obtained and administered by alternative health practitioners to their patients. A formulation called 'TD DMPS' (transdermal DMPS) is in use, despite the fact there is no published literature to support that the agent is absorbed transdermally. The investigators hypothesis is that DMPS is not absorbed through the skin. The investigators plan to apply TD DMPS to healthy volunteers and then test serum for presence of DMPS. In addition the investigators will measure urinary mercury concentrations pre and post DMPS application.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mpi Dtpa Kit - Chelate

Condition Name

Condition Name for Mpi Dtpa Kit - Chelate
Intervention Trials
Iron Deficiency Anemia 3
COVID19 3
COVID-19 2
Contrast Enhancement in Magnetic Resonance Imaging 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mpi Dtpa Kit - Chelate
Intervention Trials
COVID-19 5
Anemia, Iron-Deficiency 5
Anemia 5
Deficiency Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mpi Dtpa Kit - Chelate

Trials by Country

Trials by Country for Mpi Dtpa Kit - Chelate
Location Trials
United States 30
Japan 14
Italy 9
Germany 7
China 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mpi Dtpa Kit - Chelate
Location Trials
Missouri 3
California 3
Ohio 3
Maryland 2
South Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mpi Dtpa Kit - Chelate

Clinical Trial Phase

Clinical Trial Phase for Mpi Dtpa Kit - Chelate
Clinical Trial Phase Trials
Phase 4 7
Phase 3 7
Phase 2/Phase 3 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mpi Dtpa Kit - Chelate
Clinical Trial Phase Trials
Completed 16
Unknown status 5
Active, not recruiting 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mpi Dtpa Kit - Chelate

Sponsor Name

Sponsor Name for Mpi Dtpa Kit - Chelate
Sponsor Trials
National Cancer Institute (NCI) 2
Bayer 2
Replicor Inc. 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mpi Dtpa Kit - Chelate
Sponsor Trials
Other 26
Industry 14
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

MPI DTPA Kit - Chelate: Clinical Trials, Market Analysis, and Projections

Last updated: January 7, 2025

Introduction

The MPI DTPA Kit - Chelate, a radiopharmaceutical agent, is widely used in nuclear medicine for various diagnostic purposes, including renal imaging and the estimation of glomerular filtration rate (GFR). Here, we will delve into the current state of clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Usage

Diagnostic Applications

The MPI DTPA Kit - Chelate is primarily used for renal imaging and to assess renal perfusion and GFR. It is administered intravenously, and its clearance is used to estimate GFR, which is crucial for diagnosing and monitoring renal function[3].

Study Protocols

In clinical settings, patients are typically injected with a bolus of 99mTc-DTPA followed by a saline flush. The procedure involves dynamic and static imaging to capture the renal function and excretion of the radiotracer. For example, a study involving sequential injections of 99mTc-DTPA and 99mTc-MAG3 highlighted the importance of precise imaging protocols to ensure accurate data collection[1].

Safety and Contraindications

While the MPI DTPA Kit - Chelate is generally safe, it is contraindicated in pregnant women, nursing mothers, and children unless the benefits outweigh the potential risks. Aseptic procedures must be followed during preparation and administration to avoid adverse reactions[3].

Market Analysis

Current Market Trends

The market for radiopharmaceuticals, including the MPI DTPA Kit - Chelate, is driven by the increasing demand for diagnostic imaging in various medical specialties. The global radiopharmaceutical market is expected to grow due to advancements in nuclear medicine and the rising incidence of diseases that require diagnostic imaging.

Competitive Landscape

The market for DTPA kits is competitive, with several manufacturers providing similar products. However, the MPI DTPA Kit - Chelate stands out due to its reliability, rapid blood clearance, and optimal imaging times. The inclusion of ascorbic acid in the reagent aids in maintaining the reduced state of tin, enhancing stability and labeling efficiency[3].

Economic Considerations

The cost-effectiveness of the MPI DTPA Kit - Chelate is a significant factor in its market appeal. The reagent is usable for six hours after labeling, and there are no delivery charges when ordered with other MPI products, making it an economical choice for healthcare providers[2].

Market Projections

Growth Drivers

The growth of the MPI DTPA Kit - Chelate market is expected to be driven by several factors:

  • Increasing Demand for Diagnostic Imaging: The rising need for accurate and early diagnosis of renal and other diseases will continue to drive the demand for radiopharmaceuticals.
  • Advancements in Technology: Improvements in imaging technologies and protocols will enhance the utility and accuracy of the MPI DTPA Kit - Chelate.
  • Expanding Healthcare Infrastructure: The growth of healthcare infrastructure in emerging markets will increase access to diagnostic imaging services, further boosting demand[3].

Market Size and Forecast

The global radiopharmaceutical market, which includes the MPI DTPA Kit - Chelate, is projected to grow significantly over the next few years. According to industry reports, the market is expected to reach billions of dollars by 2025, with a compound annual growth rate (CAGR) of around 10%.

Regional Analysis

The market for the MPI DTPA Kit - Chelate is expected to be strong in regions with well-developed healthcare systems, such as North America and Europe. However, emerging markets in Asia-Pacific and Latin America are also expected to contribute significantly to the growth due to increasing healthcare spending and infrastructure development.

Regulatory Considerations

Licensing and Compliance

The use of radiopharmaceuticals, including the MPI DTPA Kit - Chelate, is heavily regulated. Healthcare providers must comply with strict guidelines and obtain necessary licenses to handle and administer these agents. Regulatory bodies such as the Nuclear Regulatory Commission (NRC) play a crucial role in ensuring safety and compliance[5].

Safety Standards

Manufacturers must adhere to stringent safety standards to ensure the quality and safety of the MPI DTPA Kit - Chelate. This includes maintaining sterile and pyrogen-free conditions during preparation and ensuring the correct labeling and dosing of the radiotracer[3].

Key Takeaways

  • Clinical Utility: The MPI DTPA Kit - Chelate is a valuable tool for renal imaging and GFR estimation.
  • Market Growth: The market is expected to grow driven by increasing demand for diagnostic imaging and technological advancements.
  • Regulatory Compliance: Strict adherence to regulatory guidelines is essential for the safe use of this radiopharmaceutical.
  • Economic Viability: The kit offers economic benefits due to its usability and delivery terms.

FAQs

What is the primary use of the MPI DTPA Kit - Chelate?

The primary use of the MPI DTPA Kit - Chelate is for renal imaging and to estimate glomerular filtration rate (GFR).

What are the contraindications for the MPI DTPA Kit - Chelate?

The MPI DTPA Kit - Chelate is contraindicated in pregnant women, nursing mothers, and children unless the benefits outweigh the potential risks.

How is the MPI DTPA Kit - Chelate administered?

The MPI DTPA Kit - Chelate is administered intravenously, typically followed by a saline flush.

What are the key factors driving the market growth for the MPI DTPA Kit - Chelate?

The market growth is driven by increasing demand for diagnostic imaging, advancements in technology, and expanding healthcare infrastructure.

What regulatory bodies oversee the use of the MPI DTPA Kit - Chelate?

Regulatory bodies such as the Nuclear Regulatory Commission (NRC) oversee the use of radiopharmaceuticals, including the MPI DTPA Kit - Chelate.

Sources

  1. Routine Renal Scintigraphy with Sequential Injections of 99mTc-DTPA and 99mTc-MAG3. Journal of Nuclear Medicine Technology, Vol. 22, No. 4.
  2. Advertising - Journal of Nuclear Medicine. Journal of Nuclear Medicine, Vol. 18, No. 6.
  3. Technetium Tc 99m Pentetate Kit (Chelate). Journal of Nuclear Medicine, Vol. 18, No. 5.
  4. MPI Indium DTPA In 111. Journal of Nuclear Medicine, Vol. 23, No. 6.
  5. Authorization To Prepare Radiopharmaceutical Reagent Kits & Elute Generators. Nuclear Regulatory Commission.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.